Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Vaibhav Sahai(University of Michigan), Antoine Hollebecque(Institut Gustave Roussy), Gina M. Vaccaro(Providence Portland Medical Center), Davide Melisi(University of Verona), Raed Moh’d Taiseer Al-Rajabi(The University of Kansas Cancer Center), Andrew Scott Paulson(Baylor University Medical Center), Mitesh J. Borad(WinnMed), David Gallinson(Morristown Medical Center), Adrian Murphy(Johns Hopkins University), Do‐Youn Oh(Seoul National University Hospital), Efrat Dotan(Fox Chase Cancer Center), Daniel V.T. Catenacci(University of Chicago), Eric Van Cutsem(KU Leuven), Tao Ji(Incyte (United States)), Christine Lihou(Incyte (United States)), Hui‐Ling Zhen(Incyte (United States)), Luis Féliz(Incyte (United States)), Arndt Vogel(Medizinische Hochschule Hannover)
The Lancet Oncology
March 20, 2020
10.1016/s1470-2045(20)30109-1
Cited by 1,561Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis